Claims
- 1. A combination composition which consists essentially of:(a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; and (b) coenzyme Q10.
- 2. A combination which consists essentially of:(a) propionyl L-carnitine or a pharmaceutically acceptable salt thereof: (b) coenzyme Q10; and (c) at least one “-carnitine-” selected from the group consisting of L-carnitine, acetyl L-carnitine, valery L-carnitine, isovalery L-carnitine and butyryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.
- 3. The composition of claim 1 or 2, wherein the weight ratio (a):(b) ranges from 1:0.05 to 1:0.1.
- 4. The composition of claim 1 or 2, wherein the weight ratio (a):(b) ranges from 1:0.05 to 1:0.1.
- 5. The composition of claim 1 or 2, wherein the pharmacologically acceptable salt is selected from the group consisting of chloride; bromide; iodide, aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane syulphonate.
- 6. The composition of claim 1 or claim 2, orally administrable, in the form of a dietary supplement.
- 7. The composition of claim 1 or claim 2, orally, parenterally, rectally, sublingually or transdermally administrable, in the form of a medicament.
- 8. The dietary supplement of claim 6, in solid, semi-solid or liquid form.
- 9. The composition of claim 7, manufactured in solid, semi-solid or liquid form.
- 10. The dietary supplement of claim 8, in the form of tablets, lozenges, pills, capsules, granulates, syrups, vials or drops.
- 11. The composition of claim 9, in the form of tablets, lozenges, pills, capsules, graulates, syrups, vials or drops.
- 12. A method for the treatment of vasculopathic, cardiac, central and peripheral cerebral disturbances and of learning disorders or disorders related to ageing comprises administering to a subject in need thereof a combination composition consisting essentially of the following components:(a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) coenzyme Q10.
- 13. A method for the treatment of vasculopathic, cardiac, central and peripheral cerebral disturbances and of learning disorders or disorders related to ageing which comprises administering to a subject in need thereof a combination composition consisting essentially of the following components:(a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, (b) coenzyme Q10, and (c) at least one carnitine selected from the group consisting of L-carnitine, acetyl L-carnitine, valeryl L-carnitine, isovaleryl L-carnitine and butyryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
RM2000A0106 |
Mar 2000 |
IT |
|
Parent Case Info
This application is the US national phase of international application PCT/IT01/00081 filed Feb. 20,2001 which designated the U.S.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/IT01/00081 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO01/64203 |
9/7/2001 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
6232346 |
Sole et al. |
May 2001 |
B1 |
Foreign Referenced Citations (6)
Number |
Date |
Country |
WO 9841113 |
Sep 1998 |
WO |
WO 9843617 |
Oct 1998 |
WO |
WO 0000183 |
Jan 2000 |
WO |
WO 0062773 |
Oct 2000 |
WO |
WO 0064426 |
Nov 2000 |
WO |
WO 0174361 |
Oct 2001 |
WO |